Integral Health Asset Management, LLC Incyte Corp Transaction History

Integral Health Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$66.18 - $83.18 $1.19 Million - $1.5 Million	-18,000 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$66.02 - $79.71 $792,240 - $956,519	-12,000 Reduced 40.0%	18,000 $1.43 Million
Q4 2021 Feb 02, 2022	BUY	$63.34 - $74.11 $1.9 Million - $2.22 Million	30,000 New	30,000 $2.2 Million
Q3 2020 Nov 16, 2020	SELL	$85.07 - $109.69 $850,699 - $1.1 Million	-10,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $741,800 - $1.09 Million	10,000 New	10,000 $1.04 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $1.58 Million - $2.15 Million	-25,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$73.04 - $95.72 $1.83 Million - $2.39 Million	25,000 New	25,000 $2.18 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.